Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
CTO
Citius Oncology, Inc.CTOR
1.6×-0.3×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
143.7×+142×
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
5.1×+0.7×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
+4.3×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.9×-0.7×

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s price / book?
TuHURA Biosciences, Inc. (HURA) reported price / book of 4.4× in Q1 2026.
How has TuHURA Biosciences, Inc.'s price / book changed year-over-year?
TuHURA Biosciences, Inc.'s price / book decreased by 68.6% year-over-year, from 13.9× to 4.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.